Background Patients with melanoma that progresses on ipilimumab and, if BRAF V600 mutant-positive, a BRAF or MEK inhibitor or both, have few treatment options. We assessed the effi cacy and safety of two pembrolizumab doses versus investigator-choice chemotherapy in patients with ipilimumab-refractory melanoma.
Introduction
In the past 4 years, melanoma treatment has remarkably improved because of the successful clinical development of therapies targeting the MAPK pathway and the development of immune checkpoint inhibitors that reactivate the anticancer immune response. 1 The CTLA-4
inhibitor ipilimumab improved overall survival in two randomised trials leading to its regulatory approval for the treatment of advanced melanoma in many countries. 2, 3 However, when disease progresses on or after ipilimumab, and BRAF inhibitor-based therapy if disease is BRAF When T cells infi ltrate tumours, they produce interferon-mediated signals that lead cells in the tumour microenvironment to express PD-L1, which inhibits T cells through engagement of the PD-1 receptor. 5 Preclinical studies provided the rationale for the use of antibodies that block PD-1 or PD-L1 to treat cancer. 6, 7 Studies have provided clinical evidence of anti-tumour activity in melanoma, renal cell carcinoma, and lung and bladder cancer, among others. [8] [9] [10] [11] [12] [13] In a phase 1b trial, the anti-PD-1 antibody pembrolizumab (formerly MK-3475 and lambrolizumab) showed antitumour activity and a manageable safety profi le in patients with advanced melanoma, including those with disease refractory to ipilimumab and, when indicated, BRAF inhibitors. 10, 11 Here, we present results of KEYNOTE-002, the defi nitive assessment of pembrolizumab in this population.
Methods

Study design and participants
KEYNOTE-002 is an international, randomised, controlled, phase 2 clinical trial comparing two pembrolizumab doses with investigator-choice chemotherapy. Eligible patients were aged 18 years or older and had histologically or cytologically confi rmed unresectable stage III or stage IV melanoma not amenable to local therapy; confi rmed disease progression 14 within 24 weeks of the last ipilimumab dose (minimum two doses, 3 mg/kg once every 3 weeks); previous BRAF or MEK inhibitor therapy or both (if BRAF V600 mutant-positive); resolution or improvement of ipilimumab-related adverse events to grade 0-1 and prednisone dose 10 mg/day or less for at least 2 weeks before the fi rst dose of study drug; Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; measurable disease per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1); and values within the prespecifi ed range for absolute neutrophil count (≥1500 cells per mL), platelets (≥100 000 cells per mL), haemoglobin (≥90 g/L), serum creatinine (≤1·5 upper limit of normal [ULN]), serum total bilirubin (≤1·5 ULN or direct bilirubin ≤ULN for patients with total bilirubin concentrations >1·5 ULN), aspartate and alanine aminotransferases (≤2·5 ULN or ≤5 ULN for patients with liver metastases), international normalised ratio or prothrombin time (≤1·5 ULN if not using anticoagulants), and activated partial thromboplastin time (≤1·5 ULN if not using anticoagulants). Patients had a washout period of at least 4 weeks between the last dose of the most recent therapy and the fi rst dose of pembrolizumab. We excluded patients with known active brain metastases or carcinomatous meningitis, active autoimmune disease, active infection requiring systemic therapy, known history of HIV infection, active hepatitis B virus or hepatitis C virus infection, a history of grade 4 ipilimumab-related adverse events or grade 3 ipilimumab-related adverse events lasting longer than 12 weeks, or previous treatment with any other anti-PD-1 or anti-PD-L1 therapy.
The study was conducted in accordance with the protocol, good clinical practice standards, and the
Research in context
Evidence before this study Throughout the writing process and most recently on April 30, 2015, we did an extensive search of PubMed for studies of PD-L1 and PD-1 in advanced cancers, including melanoma. This search was not limited by date. Search terms were "PD-1 OR PD-L1 OR MK-3475 OR lambrolizumab OR nivolumab OR BMS-936558 OR MPDL3280A OR BMS-936559". Two studies (Weber et al, 2015, and report fi ndings for nivolumab that corroborate our data. We also searched PubMed to identify treatment options for ipilimumab-refractory melanoma, without any language restrictions. Apart from cytotoxic chemotherapy, we identifi ed no standard treatment options for ipilimumab-refractory melanoma. Although some studies have shown effi cacy for other anti-PD-1 and PD-L1 inhibitors after ipilimumab, these were not controlled and the sample sizes were small.
Added value of this study
Our study is, to the best of our knowledge, the largest reported randomised, controlled trial of an anti-PD-1 or anti-PD-L1 drug for ipilimumab-refractory melanoma. Results of this study confi rm the effi cacy and safety of pembrolizumab and the absence of a signifi cant diff erence in outcomes between pembrolizumab doses of 2 mg/kg and 10 mg/kg given once every 3 weeks, as observed in an earlier phase 1b study of patients with ipilimumab-refractory melanoma. More important, the study shows the superiority of pembrolizumab over cytotoxic chemotherapy, the current standard-of-care therapy, to improve progression-free survival in ipilimumab-refractory melanoma. Our data are arguably of greater clinical relevance than are the data reported for nivolumab in this population because our study included patients with BRAF V600 -mutant melanoma and we report progression-free survival and patient-reported outcomes data.
Implications of all the available evidence
Overall, these fi ndings establish pembrolizumab as a new standard of care for melanoma and support the accelerated approval granted by the US Food and Drug Administration for the use of pembrolizumab 2 mg/kg once every 3 weeks by patients with unresectable or metastatic melanoma whose disease progressed after ipilimumab and, if BRAF Declaration of Helsinki. The protocol and subsequent amendments were approved by the appropriate institutional review board or ethics committee at each participating institution. All patients provided voluntary written informed consent. An external data monitoring committee reviewed interim trial results to ensure patient safety and to recommend whether the trial should continue in accordance with the protocol.
Randomisation and masking
Patients were randomly assigned (1:1:1) to pembrolizumab 2 mg/kg or pembrolizumab 10 mg/kg given intravenously every 3 weeks or investigator-choice chemotherapy (paclitaxel plus carboplatin, paclitaxel, carboplatin [eliminated with protocol amendment one], dacarbazine, or oral temozolomide). Randomisation was stratifi ed by ECOG performance status (0 vs 1), lactate dehydrogenase concentration (normal vs raised [ie, ≥110% upper limit of normal]), and BRAF status (wild type vs V600 mutantpositive). Block randomisation with a block size of six in each stratum was used. After all screening procedures were complete, a centralised interactive voice-response system with or without web functionality was used to allocate patients to treatment. Before entering information into the system, the investigator was to identify which chemotherapy regimen would be given in the event the patient was allocated to the chemotherapy group. Individual treatment assignment between pembrolizumab and chemotherapy was open label; investigators and patients were masked to assignment to pembrolizumab dose. A designated pharmacist at each site who was unmasked prepared the pembrolizumab dose so that it could be administered to the patient in a masked fashion. The sponsor was masked to all treatment assignments in the statistical analyses, as well as treatment-level analysis results. A non-Merck unmasked statistician generated interim analysis reports for external data monitoring committee review for the fi rst and second interim analyses. After the second interim analysis, the external data monitoring committee indicated that the progressionfree survival superiority objective had been met and recommended unmasking the study for reporting purposes but continuing the study for overall survival at the fi nal analysis. At the second interim analysis and after the data monitoring committee's recommendation, the treatment group was unmasked; investigators and patients remained masked to the pembrolizumab dose.
Procedures
Patients were given their fi rst dose of study treatment within 3 days of treatment assignment. Chemotherapy was given per the approved product information and standard practice protocols at each institution and continued until evidence of disease progression. Patients in the chemotherapy group with documented and verifi ed disease progression at or after week 12 who met the relevant eligibility criteria could cross over to receive pembrolizumab after a washout period of at least 28 days from the last dose of chemotherapy; patients who crossed over were randomly assigned to one of the two pembrolizumab doses in a double-blind manner. Pembrolizumab was continued until disease progression, unacceptable toxicity, consent withdrawal, physician decision, or other reason. If the week 12 scan showed disease progression, patients were allowed to continue treatment until progression was confi rmed at a subsequent scan to account for atypical response patterns. 14 For purposes of statistical analysis, progressive disease per RECIST v1.1 was defi ned as the fi rst documented disease progression, irrespective of confi rmation at a second assessment. The criteria for removal of a patient from the study and details of permitted interruptions of study treatment are available in the study protocol (appendix).
Tumour assessments were done before starting study treatment (baseline), at week 12, every 6 weeks through to week 48, and every 12 weeks thereafter. After study treatment discontinuation, patients were contacted every 12 weeks to assess survival. Adverse events, laboratory values, and vital signs were assessed regularly throughout the study and graded per the Common Terminology Criteria for Adverse Events, version 4.0. We assessed patient-reported health-related quality of life and disease symptoms using the European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30).
Outcomes
The primary endpoint at the second interim analysis was progression-free survival, the time from randomisation to fi rst documented disease progression per RECIST v1.1 by independent central review or death from any cause, whichever occurred fi rst. All scans were evaluated by independent central review. The independent radiologists were masked to treatment assignments, identifying patient characteristics, and investigator-assessed fi ndings. Overall survival, the time from randomisation to death from any cause, will be the primary endpoint at fi nal analysis. Progression-free survival was also assessed by investigator review. Both progression-free survival assessed per RECIST v1.1 by investigator review and progression-free survival assessed per modifi ed RECIST v1.1 (where confi rmation of disease progression on a scan ≥4 weeks after initial evidence of disease progression was required 14 ) by investigator review were done as sensitivity analyses. Secondary endpoints included the proportion of patients who had an objective response, the proportion of patients who had a complete or partial response as assessed per RECIST v1.1 by central review (patients without post-baseline disease assessment were considered to be non-responders); response duration, the time from best overall response of complete or partial response until disease progression; and safety. Prespecifi ed exploratory endpoints included change from baseline to week 12 in the global health status and See Online for appendix quality-of-life score of the EORTC QLQ-C30 questionnaire, with other functional and symptom subscales as supportive evidence. Per the prespecifi ed analysis plan, the EORTC QLQ-C30 data collected at weeks 24 and 36 would be analysed only if the completion rate in the chemotherapy treatment group was higher than 50% at week 24 or 36.
Statistical analysis
The sample size of the study was determined on the basis of the overall survival endpoint at the fi nal analysis. We estimated that with 370 events (deaths) among a total of 510 patients in the three treatment groups (170 patients per group), and assuming that the median overall survival in the chemotherapy group is 6 months and the hazard ratio between pembrolizumab and chemotherapy is 0·65, the study would have at least 90% power to detect the overall survival diff erence in at least one pembrolizumab group using the Hochberg testing procedure 15 at a 2% α level (one sided). Before recommendations from the external data monitoring committee to unmask the study treatment allocation, both the fi rst and second interim analyses were done by an unmasked statistician. The fi rst planned interim analysis on Nov 13, 2013, focused on detecting whether one pembrolizumab dose was inferior to the other, with the possible decision of discontinuing one pembrolizumab dose, and safety. The external data monitoring committee did not identify any concerns when they reviewed the fi rst interim analysis results, and the study proceeded as planned. The second interim analysis (reported here) was planned to occur after at least 270 progression-free survival events (about 180 events between one pembrolizumab group and the chemotherapy group) occurred, at which time 210 deaths were anticipated. At the second interim analysis, the study had 92% power to detect a hazard ratio (HR) of 0·55 for progression-free survival at a one-sided α of 0·25% between one pembrolizumab group and the chemotherapy group. The study would be considered positive at this interim analysis if the one-sided p value for progression-free or overall survival was lower than 0·0025 in either pembrolizumab group compared with the chemotherapy group; based on 270 progression-free survival events, the observed HR that would meet the criterion for a positive trial was 0·66. Because the study completed enrolment 3 months earlier than expected and the death rate was lower than was expected, the timing of the second interim analysis was driven by the targeted number of deaths. Therefore, the number of progression-free survival events at the time of the second interim analysis was higher than that prespecifi ed in the statistical analysis plan. survival events. Although overall survival was not the primary endpoint of the second interim analysis, comparisons for each pembrolizumab group compared with the chemotherapy group were tested at an α of 0·25%. Because the prespecifi ed threshold for declaring superiority of pembrolizumab over chemotherapy was met for progression-free but not overall survival, the data monitoring committee recommended that the study could be unmasked but that follow-up should continue as planned. Final overall survival analysis will be done when 370 deaths have occurred.
All statistical analyses were done with SAS (version 9.3). We did all effi cacy analyses in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study treatment. KaplanMeier methods were used to estimate progression-free and overall survival, duration of response, and time to the fi rst treatment-related grade 3-4 adverse event.
We analysed between-group comparisons of progressionfree and overall survival with the stratifi ed log-rank test. We calculated HRs and associated 95% CIs with a stratifi ed Cox proportional hazard model with Efron's method of tie handling. 16 The stratifi ed Miettinen and Nurminen method 17 was used to compare the the proportion of patients achieving an objective response between treatment groups. The same stratifi cation factors used for randomisation were used in all stratifi ed effi cacy analyses. A constrained longitudinal data analysis model was used to analyse diff erences in EORTC QLQ-C30 score changes between treatment groups. This study is registered with ClinicalTrials.gov, number NCT01704287.
Role of the funding source
Merck Sharp & Dohme, a subsidiary of Merck & Co, sponsored this study. Along with academic advisers, representatives of the sponsor participated in designing the study. Data collected by the investigators and their site personnel were analysed and interpreted by senior academic authors and representatives of the sponsor. All authors had full access to the data used to prepare this manuscript. The corresponding author wrote the fi rst draft of the manuscript, with subsequent involvement of all authors, including those employed by the study sponsor. The corresponding author had the fi nal responsibility to submit for publication.
Results
Between Nov 30, 2012, and Nov 13, 2013, we enrolled 540 patients from 73 sites in 12 countries (full site list available in the appendix). We randomly allocated patients to pembrolizumab 2 mg/kg (n=180), pem brolizumab 10 mg/kg (n=181), or chemotherapy (n=179 [42 patients to paclitaxel plus carboplatin, 28 to paclitaxel, 13 to carboplatin, 45 to dacarbazine, and 43 to temozolomide; eight did not receive treatment]; fi gure 1). Patient characteristics were well balanced across study groups (table 1) . Visceral metastases (stage M1c) and elevated lactate dehydrogenase concentrations, poor prognostic factors for advanced melanoma, were observed in 446 (83%) and 218 (40%) of the 540 patients, respectively, at baseline. Most patients received two or more previous lines of therapy for advanced disease, including chemotherapy in just under half of the patients; a quarter of patients had received BRAF or MEK inhibitor ( Based on 410 total progression-free survival events (RECIST v1.1, central review), the study met the pre-specifi ed criteria to show signifi cant improvement in progression-free survival, with hazard ratios of 0·57 (95% CI 0·45-0·73) for pembrolizumab 2 mg/kg and 0·50 (95% CI 0·39-0·64) for 10 mg/kg compared with chemotherapy (p<0·0001 for both; Table 2 : Summary of effi cacy in the intention-to-treat population scheduled post-baseline tumour assessment in all study groups because more than half of patients had progressed by week 12 (fi gure 2A, table 2). By 6 months, about a third of patients assigned to pembrolizumab were progression free (34% assigned to 2 mg/kg and 38% assigned to 10 mg/kg), whereas only 16% assigned to chemotherapy had not progressed (table 2) . At 9 months, about a quarter of patients assigned to pembrolizumab were progression free (24% assigned to 2 mg/kg and 29% assigned to 10 mg/ kg) compared with 8% assigned to chemotherapy (table 2) .
In a post-hoc analysis, restricted mean progression-free survival time based on the area under the Kaplan-Meier curve up to 12 months 19 was 5·4 months (95% CI 4·7-6·0) for the pembrolizumab 2 mg/kg group, 5·8 months (5·1-6·4) for the pembrolizumab 10 mg/kg group, and 3·6 months (3·2-4·1) for the chemotherapy group. Pembrolizumab also signifi cantly improved progressionfree survival when assessed by investigator review, with a larger treatment eff ect for pembrolizumab (table 2) and a greater separation of the curves (fi gure 2B), although possible investigator bias in a partly open-label trial such as this might explain the greater eff ect size. A protocolspecifi ed supportive analysis of progression-free survival per investigator review that assessed progression only if it was observed in two consecutive scans also showed a signifi cant treatment eff ect favouring pembrolizumab (table 2, fi gure 2C). The superiority of both pembrolizumab doses was evident in all prespecifi ed patient subgroups (fi gure 3).
Immature overall survival data, which were evaluated at a small α level at this interim analysis, did not meet the prespecifi ed 0·25% superiority threshold for each pembrolizumab dose compared with chemotherapy (data not shown). Final overall survival will be assessed after 370 deaths.
On independent central review, 38 (21%) patients in the pembrolizumab 2 mg/kg group and 46 (25%) in the 10 mg/kg group responded to treatment as per RECIST v1.1 criteria, compared with eight (4%) in the chemotherapy group (p<0·0001 for each pembrolizumab dose vs chemotherapy). Median time to response was 13 weeks (IQR 12-18) in the pembrolizumab 2 mg/kg group, 15 weeks (12-18) in the pembrolizumab 10 mg/kg group, and 13 weeks (12) (13) (14) (15) (16) (17) (18) in the chemotherapy group. At the time of analysis 35 (92%) of 38 responders in the pembrolizumab 2 mg/kg group, 40 (87%) of 46 responders in the pembrolizumab 10 mg/kg group, and fi ve (63%) of eight responders in the chemotherapy group remained progression free. Median duration of response was not reached in either pembrolizumab group and was 37 weeks (IQR 12-41) in the chemotherapy group (table 2) . Based on the prespecifi ed futility rule, the proportion of responses did not diff er between the two pembrolizumab groups. As such, neither pembrolizumab dose was discontinued at the fi rst interim analysis. 35 (19%) of 180 patients in the pembrolizumab 2 mg/kg group and 37 (20%) of 181 patients in the pembrolizumab 10 mg/kg group were treated beyond initial evidence of disease progression.
Of the 540 patients enrolled, 528 received at least one dose of study treatment and were assessed for safety (fi gure 1). Median time on treatment was 113 days (range 1-499) in the pembrolizumab 2 mg/kg group, 145 days (1-505) in the pembrolizumab 10 mg/kg group, and 
days (1-335) in the chemotherapy group (appendix).
There were no treatment-related deaths. One death in a man aged 75 years treated with pembrolizumab 2 mg/kg was reported by the investigator to be possibly related to treatment. The day after the fi rst pembrolizumab dose, the patient presented with a bleeding pelvic mass causing severe pain. He was also found to have melaena, possibly from existing small bowel metastases. The patient died 3 days later. Given his age and overall poor clinical condition, comprehensive investigations were not done, and the cause of death was listed as unknown. After the analysis cutoff date, the causality of this death was changed by the investigator to be unrelated to treatment. Treatment interruption as a result of treatment-related adverse events was needed in 15 (8%) of 178 patients treated with pembrolizumab 2 mg/kg, 15 (8%) of 179 patients treated with pembrolizumab 10 mg/kg, and 30 (18%) of 171 patients treated with chemotherapy. Treatment-related adverse events led to permanent treatment discon tinuation in fi ve (3%) patients given pembroli zumab 2 mg/kg, 12 (7%) given pembrolizumab 10 mg/kg, and 10 (6%) patients given chemotherapy. Treatment-related serious adverse events occurred at a similar frequency across treatment groups (table 3) . The most common serious treatment-related adverse events observed in the combined pembrolizumab treatment groups were diarrhoea and pneumonitis (three [1%] of 357 patients each). Treatment-related adverse events more common with chemotherapy were alopecia, anaemia, decreased appetite, fatigue, nausea, and vomiting; those more frequent with pembrolizumab were rash and pruritus (table 3) . Consistent with previous experience, the adverse event profi les of the 2 mg/kg and 10 mg/kg doses were generally similar. 10, 11 Adverse events of a potentially immune-mediated nature were infrequent, and none were of grade 4 or 5 severity (appendix). These events were generally manageable with supportive care, withholding treatment, or corticosteroid therapy.
Baseline EORTC QLQ-C30 global health status and quality-of-life scores were similar across treatment groups. The least squares mean change from baseline to week 12 in the score was -2·60 (95% CI -6·15 to 0·96) in the pembrolizumab 2 mg/kg group, -2·55 (-5·99 to 0·89) in the 10 mg/kg group, and -9·13 (-12·86 to -5·39) in the chemotherapy group (appendix). The least squares mean change signifi cantly diff ered between the 2 mg/kg pembrolizumab and chemotherapy groups (6·53, 95% CI 1·53-11·53; p=0·011) and the 10 mg/kg pembrolizumab and chemotherapy groups (6·57, 1·65-11·50; p=0·009 
Discussion
In this population of patients with advanced melanoma that progressed on ipilimumab and, in many cases, on chemotherapy or MAPK pathway inhibitors, pembrolizumab reduced the risk of disease progression or death compared with investigator-choice standard-of-care chemotherapy. Although median progression-free survival values were similar, around the time of the fi rst scheduled tumour assessment at week 12 in all treatment groups, the Kaplan-Meier curves separated dramatically thereafter, indicating the treatment eff ect.
The ability of ipilimumab-refractory disease to respond to pembrolizumab is probably a refl ection of the diff erent mechanisms by which anti-CTLA-4 and anti-PD-1 therapies stimulate an anti-tumour T-cell response. CTLA-4 blockade broadens the immune response, evidenced by an increased T-cell receptor repertoire leading to increased tumour infi ltration, [20] [21] [22] [23] whereas PD-1 blockade induces intratumoural T-cell Adverse events are listed in order of descending frequency in the total study population (patients who had at least one study drug dose). *One additional patient treated with pembrolizumab 10 mg/kg had two serious treatment-related adverse events of unspecifi ed severity. †One additional patient in the pembrolizumab 2 mg/kg treatment group died because of an adverse events considered to be possibly related to treatment at the time of data cutoff (full details provided in text). ‡ One additional patient treated with pembrolizumab 10 mg/kg had arthralgia of unspecifi ed severity. Five times more patients had an objective response with pembrolizumab than did those assigned to chemotherapy. This marked improvement is particularly meaningful because of the superior response durability observed with pembrolizumab, although longer followup is warranted to fully appreciate response duration. Most patients in this trial had disease that progressed on several lines of therapy in the metastatic setting, including chemotherapy in a half of patients. In addition, all patients with BRAF V600 -mutant-positive melanoma had received treatment with a MAPK pathway inhibitor. Overall, less than 5% of this population responded when allocated to investigator's choice of chemotherapy. These results support the Food and Drug Administration's accelerated approval of pembrolizumab in this poorprognosis population.
Although our study was not powered to assess the equivalence of the two pembrolizumab doses, the results of the two interim analyses do not suggest a signifi cant, clinically meaningful, diff erence between the doses. The higher number of responses in the pembrolizumab 10 mg/kg treatment group than in the 2 mg/kg group might be due to random variation. The absence of a signifi cant diff erence between the pembrolizumab doses is consistent with fi ndings in a similar population treated in the KEYNOTE-001 study. 10, 11 Taken together, there is no evidence that one pembrolizumab dosing regimen is superior to another. Therefore, the minimally eff ective pembrolizumab dose of 2 mg/kg given every 3 weeks is recommended for further use.
Pembrolizumab was well tolerated compared with chemotherapy, with fe wer treatment-related and grade 3-4 adverse events in the pembrolizumab groups despite an approximately two-fold longer duration of exposure. Potentially immune-mediated adverse events such as hypothyroidism, hypophysitis, colitis, pneumonitis, hepatitis, and nephritis were observed with pembrolizumab, although they were infrequent and mostly of grade 1 or 2 severity. Of note, there were no cases of new-onset type 1 diabetes mellitus. Potentially immune-mediated events were generally manageable with immunosuppressive therapy and treatment interruption or discontinuation as appropriate. The benefi t of pembrolizumab is further strengthened by the favourable health-related quality-of-life scores compared with chemotherapy.
Two recent studies of nivolumab (an anti-PD-1 antibody) have reported an improvement in objective responses compared with chemotherapy in patients who had previously received ipilimumab 28 and improvement in overall survival compared with chemotherapy in patients with BRAF V600 wild-type melanoma. 29 Furthermore, pembrolizumab given to patients who were ipilimumab treatment-naive showed improvement in responses, progression-free survival, and overall survival compared with ipilimumab. 30 Combined with our study fi ndings, these data support the remarkable activity of PD-1 blockade in patients with advanced melanoma. Evaluation of the eff ect of PD-1 blockade on overall survival relative to standard-of-care treatment is continuing in KEYNOTE-002 and other studies. The assessment of biomarkers and studies of combination regimens are also ongoing to improve further the clinical outcomes of patients with advanced melanoma. Analyses of biomarkers and the relation between PD-L1 expression and outcomes in this study are continuing and will be reported with the fi nal overall survival analysis. Overall, targeting of the PD-1 axis is a major advancement in melanoma and establishes pembrolizumab as a new standard treatment after progression on ipilimumab and other therapies. 
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